People quit NMN for four reasons, and three of them are well supported by the published evidence. That is an unusual thing to be able to say about a supplement, and it is worth saying plainly before we get to the one place where quitting may be a mistake.
One: it cost real money and nothing happened
This is the most common version, and the trials explain it rather than contradict it.
Almost everything NMN has been shown to do is a laboratory measurement. Blood NAD⁺ rises reliably — in a randomized, double-blind, placebo-controlled trial of 80 healthy middle-aged adults (n = 80), it rose significantly in every dose group at day 30 and day 60 against both placebo and baseline (all p ≤ 0.001)[1]. You cannot feel that. Nobody can. There is no sensation attached to a nicotinamide adenine dinucleotide concentration, and a product whose main documented effect is invisible to its user is a product people stop buying around month three.
At $17 to $249 a month across the brands we have verified, the question of what you are getting for the money is the right one to ask — and it is the same question we put to every format on the cost calculator.
Two: the pooled trials found what you found
If you stopped because you felt no different, you are in agreement with the meta-analyses, which is a better place to be than most supplement quitters end up.
Eight randomized trials of NMN covering 342 mostly non-diabetic middle-aged and older adults, at 250 to 2,000 mg daily for 14 days to 12 weeks, were pooled for metabolic outcomes. No significant benefit on fasting glucose, fasting insulin, glycated hemoglobin, HOMA-IR or the lipid profile [2].
A meta-analysis of muscle outcomes in adults over 60 found no significant effect of NMN on skeletal muscle index (mean difference −0.42, 95% CI −0.99 to 0.14, p = 0.14), gait speed (mean difference −0.01, 95% CI −0.08 to 0.06, p = 0.79), grip strength or the five-time chair stand test, and concluded that current evidence does not support NMN for preserving muscle mass and function in that age group [3].
And a 2026 review of 15 trials running as long as 24 weeks found no significant effect on body weight, BMI, fasting glucose, HbA1c, lipid profiles or systolic blood pressure [4].
Three independent pooling exercises, three null results on the outcomes people buy NMN for. If your own experience was “nothing changed”, the literature agrees with you.
Three: the biomarker-versus-benefit gap, stated plainly
The strongest evidence that raising NAD⁺ is not the same as getting a benefit comes from trials that did both at once.
A 12-week trial of 250 mg of NMN daily in 60 older adults is the clearest example. Its primary outcome was a stepping test, and it showed no significant difference from placebo at either 4 or 12 weeks. Blood NAD⁺ and its metabolites rose significantly; a shorter 4-meter walking time and better sleep quality scores appeared among the secondary outcomes [5]. Read the paper and you find a pre-specified primary endpoint that did not move, which is the result that carries the most weight and the one least likely to reach you.
The same shape shows up on the nicotinamide riboside side, where a randomized trial in older adults with mild cognitive impairment achieved a 2.6-fold rise in blood NAD⁺ (p < 0.001, 95% CI [17.77, 43.49]) while cognitive scores remained stable throughout the study [6]. The mechanism did exactly what it was supposed to. The outcome did not follow. That is the gap, measured, in one trial — and it runs through the whole NAD⁺ benefits literature.
Four: you were not sure it was legal to buy
NMN’s status as a lawful dietary supplement ingredient in the United States is unresolved, and people notice when a product vanishes from a major retailer or reappears under a different description. That is a regulatory question about how it may be sold, not a finding about whether it works or whether it is safe.
It is still a perfectly rational reason to stop. Supply you cannot count on is a bad basis for a daily habit, and nicotinamide riboside does not carry the same uncertainty — the branded NR ingredient in Tru Niagen has a settled US position.
Where quitting might be the wrong call
Two cases, both narrow, both worth knowing.
The first is if you are in one of the specific populations where something real was found. In postmenopausal women with prediabetes who were overweight or obese, 10 weeks of NMN increased insulin-stimulated glucose disposal measured by hyperinsulinemic-euglycemic clamp — the reference method — along with skeletal muscle insulin signaling, with no change on placebo [7]. That is a real effect in a defined group, and it is not the same claim as “NMN improves metabolism.”
The second is if you are quitting NMN in order to spend the money on something with a bigger promise. An NAD⁺ injection or an IV drip costs several times more and has no controlled outcome trials of its own at all — so trading down on evidence while trading up on price is the one move here that makes things strictly worse.
If you want a fair test before you decide
Take a dose that matches one used in a published trial rather than whatever the bottle suggests — we list them all. Give it the 8 to 12 weeks the trials ran. And decide in advance what you are measuring, because “do I feel better?” asked on a random Tuesday is answered by your sleep, your week and your expectations long before it is answered by a capsule.
If you have already done that and stopped, nothing in the published literature says you made a mistake. If you are still deciding, the oral precursor ranking is where the evidence in this category actually sits, which is not where the prices do. Cost is one of the reasons people stop, and it is not the sticker price that bites — it is the price per gram, which we rank on the NMN board.